Millennium, Takeda get conditional OK to market lymphoma drug in Europe

Millennium: The Takeda Oncology Co. and its Japanese parent said Wednesday that European regulators have granted conditional marketing authorization for Adcetris, a drug for some forms of lymphoma, a general term for cancers of the lymphatic system.

In a press release, Takeda Pharmaceutical Co. said it intends to launch Adcetris in Europe in coming weeks. (Takeda bought Cambridge-based Millennium in 2008 for $8.8 billion.)


Specifically, Millennium and Takeda said the European Commission has granted conditional marketing authorization for Adcetris to treat adults with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Since 2009, Millennium has been working on Adcetris with Seattle Genetics, (which also issued a press release Wednesday). In August 2011, the drug received Food and Drug Administration approval to be marketed in the United States.

Chris Reidy

Chris Reidy can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of